Indapamide versus beta-blocker therapy: a double-blind, crossover study in essential hypertension

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Hypertension is a prevalent cardiovascular condition requiring effective management.
• Indapamide and pindolol are established antihypertensive agents with distinct mechanisms of action.
• Comparative studies are essential to understand their relative efficacy and safety profiles.

Purpose of the Study:

• To compare the antihypertensive efficacy of indapamide (2.5 mg) and pindolol (15 mg).
• To evaluate other effects, including pulse rate changes and side effects, of both drugs.
• To assess the overall comparability of indapamide and pindolol in managing mild to moderate hypertension.

Main Methods:

• A controlled, double-blind, double-placebo, crossover clinical trial involving 24 patients.
• Patients received a 2-week placebo run-in, followed by 6 weeks of either indapamide or pindolol, then a second 2-week placebo period, and finally 6 weeks of the alternative drug.
• Blood pressure, pulse rate, laboratory data, and side effects were monitored.

Main Results:

• Both indapamide and pindolol significantly reduced systolic and diastolic blood pressure by approximately 19 mmHg and 15 mmHg, respectively (p < 0.05).
• No significant differences in blood pressure reduction were observed between the two drugs (p > 0.10).
• Pindolol significantly reduced pulse rate (from 76 to 67 beats/min; p < 0.05), while indapamide did not.
• Laboratory data remained largely unchanged, and few side effects were reported for either drug.

Conclusions:

• Indapamide and pindolol exhibit comparable antihypertensive activity at the tested dosages.
• Pindolol demonstrates an additional effect of reducing pulse rate, which indapamide does not.
• Both drugs are well-tolerated and suitable for managing mild to moderate hypertension.